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Background: Patients admitted to the emergency room with renal impairment and undergoing a contrast
computed tomography (CT) are at high risk of developing contrast nephropathy as emergency precludes sufficient
hydration prior to contrast use. The value of an ultra-high dose of intravenous N-acetylcysteine in this setting is
unknown.
Methods: From 2008 to 2010, we randomized 120 consecutive patients admitted to the emergency room with an
estimated clearance lower than 60 ml/min/1.73 m2 by MDRD (mean GFR 42 ml/min/1.73 m2) to either placebo or
6000 mg N-acetylcysteine iv one hour before contrast CT in addition to iv saline. Serum cystatin C and creatinine
were measured one hour prior to and at day 2, 4 and 10 after contrast injection. Nephrotoxicity was defined either
as 25% or 44 μmol/l increase in serum creatinine or cystatin C levels compared to baseline values.
Results: Contrast nephrotoxicity occurred in 22% of patients who received placebo (13/58) and 27% of patients
who received N-acetylcysteine (14/52, p = 0.66). Ultra-high dose intravenous N-acetylcysteine did not alter
creatinine or cystatin C levels. No secondary effects were noted within the 2 groups during follow-up.
Conclusions: An ultra-high dose of intravenous N-acetylcysteine is ineffective at preventing nephrotoxicity in
patients with renal impairment undergoing emergency contrast CT.
Trial registration: The study was registered as Clinical trial (NCT01467154).
Keywords: Computerized Tomography, Contrast media, Emergency medicine, N-acetylcysteine, NephrotoxicityBackground
Prevention of acute kidney injury (AKI) post contrast
injection remains mandatory given its association to mor-
bidity and mortality [1].
Contrast nephropathy (CN) is classically defined as an
increase in 25% or more, or as an absolute increase of
44 μmol/l of creatinine levels within three days following
contrast injection [2]. Recently, AKIN (acute kidney injury
network) and RIFLE (risk, injury, failure loss and end-
stage kidney disease) criteria have emerged to standardize
the diagnosis of AKI in hospitalized patients [3]. These
criteria are important as they correlate to mortality in* Correspondence: Pierre-Alexandre.Poletti@hcuge.ch
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reproduction in any medium, provided the orcritically and non critically ill patients [4-6]. AKIN criteria
have rarely been used for CN but appear to also predict
mortality in critically ill patients [7]. Finally, other markers
such as cystatin C or NGAL may be more sensitive to
identify CN and also to predict mortality [8] although a
definition of CN using these markers is currently lacking.
In patients undergoing elective radiological or cardio-
logic procedures, CN can be prevented by hydration,
withdrawal of diuretics and/or nephrotoxic drugs. Its
prevalence has therefore declined over the recent years
[9]. Occurrence of CN is however consistently higher in
diabetics, congestive heart failure patients, volume
depleted patients, critically ill patients and especially in
patients suffering from chronic kidney disease (CKD)
[7,10-12]. Emergency CT with contrast injection in
patients with renal impairment (eGFR < 60 ml/min)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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given the lack of sufficient time for hydration and the
lack of renal functional reserve. Finding an efficient pre-
vention for contrast nephropathy in this specific popula-
tion would be highly desirable.
N-acetylcysteine (NAC) may protect against contrast
nephropathy [13]. While hydration is clearly beneficial in
preventing CN [14], the role of NAC administration is still
uncertain and results of randomized control trials gave
conflicting results regarding its effect [15]. In addition,
NAC does not seem to prevent AKI in patients with nor-
mal renal function [16]. Intravenous NAC may be the
form of choice in emergency procedures given its rapid
availability and its ease of administration in patients whose
consciousness is altered or who cannot eat. However,
when using the iv route in emergency, higher doses of
NAC (6000 mg) may be necessary to obtain a preventive
effect as tested by Marenzi and collegues [17]. Further-
more, the Rappid study also demonstrated that high dose
iv NAC was efficient in prevention of CN, with doses de-
rived from the one used in paracetamol intoxication [18].
Indeed, NAC administered by the intravenous route may
be less effective in generating gluthatione than when given
orally [19]. Finally, in a previous study performed in pa-
tients with elevated creatinine levels undergoing emer-
gency CT-Scan, 1800 mg of NAC administered iv failed to
prevent contrast induced nephropathy [20].
The aim of the present study was therefore to determine
whether 6000 mg (ultra high dose) intravenous NAC, to
account for a dose dependent effect, was efficient in
preventing CN after emergency contrast CT-scan in pa-
tients admitted to the ER with elevated creatinine levels.
Methods
From 2008 to 2010, 124 consecutive patients were eligible
in the emergency room on account of an estimated
creatinine clearance by MDRD [21] of less than 60 ml/
min/1.73 m2 and a request for an urgent contrast CT.
Exclusion criteria were asthma, pregnancy, obstructive
nephropathy and patients’s refusal. Written consent was
obtained from every patient and from a physician inde-
pendent from the study. 4 patients refused to participate
to the study. 120 patients were randomized to placebo
or high dose iv NAC. The study was approved by the eth-
ical committee of the University Hospital of Geneva (IRB
07–121) as well as by the Swiss Agency for Therapeutic
Products (Swissmedic, N°2008DR4057).
Iohexol (Accupaque®, GE Healthcare, Opfikon) was
the contrast medium used in this study at a dose of
1.5 ml/kg to a maximum of 150 ml.
Study protocol
Patients were randomized to either placebo (0.45% saline)
or high dose (6000 mg) iv NAC (Fluimicil®, Zambon,Cadempino, Switzerland) diluted in 100 ml 0.45% saline to
be administered during the 60 minutes before the CT-
Scan. The randomization list was generated by computer,
and NAC or placebo vials were prepared and numbered
accordingly by the pharmacy. Investigators, patients and
patient’s primary physician were blinded to treatment
group. No patients in the control group received NAC
outside the study protocol.
Randomized patients were then assigned to hydration of
250 ml of 0.45% NaCl before the CT-Scan and blindly al-
located to either high dose NAC versus placebo. After the
CT-Scan, all patients received 1000 ml NaCl 0.45%. Cre-
atinine and cystatin C serum levels were collected one
hour before CT-Scan and at day 2, 4 and 10. The T0 value
for creatinine and cystatin C was the value measured be-
fore the CT-Scan. Serum Creatinine and Cystatin C were
measured by the Jaffe method, and by a nephelometric
assay respectively.
Outcome measures
The primary endpoint of the study was the occurrence
of contrast nephropathy at day 2, 4 or 10, which was de-
fined as an increase of at least 25% or 44 μmol/l in
serum creatinine level or 25% increase in cystatin C
levels at day 2, 4 or 10 compared to day 0. We also
assessed the proportion of patients with contrast ne-
phropathy regarding the biomarkers used and according
to AKIN criteria. The AKIN criteria defined a stage 1
AKI as an increase in creatinine between 150% and
199% from baseline or an absolute increase of at least
26.2 μmol/l, a stage 2 AKI as an increase between 200%
and 299% from baseline and a stage 3 AKI as an increase
of at least 300% from baseline or a creatinine concentra-
tion higher than 354 umol/l with an acute rise of at least
44 μmol/l or initiation of RRT [22].
Secondary endpoints were the mean increases in cre-
atinine and cystatin C concentrations on days 2, 4 and
10 along with the maximum increase during the time
periods from day 2 to day 10 (peak increase).
Statistical analysis
Based on a previous study [17], the proportion of patient
with nephropathy was estimated to be 15% in NAC
group and 33% in control group. To achieve a power of
90% and a two-tailed risk alpha, the minimal required
sample size has been estimated to 106 patients (Fisher’s
exact test).
All analyses were performed on an intention-to-treat
basis. Data were described as mean +/− SD. Proportions
of patients in the control and the NAC groups were
compared using Fisher’s exact test. Mean increases in
creatinine and cystatin C concentrations were compared
between the two groups by use of Mann–Whitney test.
Sensitivity analyses were performed to assess the possible
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analysis. Pearson’s correlation coefficient was computed
between creatinine and cystatin C measures for each day.
The significance level was fixed to 0.05 (two-tailed). All stat-
istical calculations were performed using R for Windows
(Version 2.11.1, R Development Core Team, 2010).Results
Data collection
Of the 120 randomized patients (Figure 1), 6 were ex-
cluded of the study because they did not undergo contrast
CT (n = 4) or presented with a renal obstruction (n = 2).
Follow up did not allow qualification of contrast ne-
phropathy in 4 patients (one in the placebo group, three
in NAC group) because they died at day 0 (n = 2) or
where lost immediately to follow up (n = 2). These patients
were excluded from the main analysis but included in the
sensitivity analysis.
In the remaining 110 patients, 8 patients did not have
creatinine and cystatin C measured at day 4 either because
they died before (n = 4), or because follow up was
interrupted (n = 2) and two for technical reasons. Cystatin
C at day 4 was not obtained in 7 other patients.
Eleven patients did not have creatinine and cystatin C
measurement at day 10, either because they died before
(n = 6), or they could not be reached (n = 4) or for tech-
nical reasons (n = 1). Seven other patients did not have
cystatin C measured at day 10.Figure 1 Flow-chart summarizing the study population.Baseline patient characteristics
At randomization, patients’ demographic and clinical
characteristics were similar between the two treatment
groups. Treatment medications were also similar be-
tween the groups. All baseline parameters are shown in
Table 1. Mean estimated GFR according to MDRD was
42 ml/min/1.73 m2. Sixty-nine (61%) of the 114 patients
had a eGFR < 45 ml/min/1.73 m2; 10 (9%) had eGFR <
30 ml/min/1.73 m2 on admission.
Outcome
Of the 114 randomized patients, data were available for
110 patients. Out of these 110 patients, 52 received
NAC and 58 the placebo. The number of patients who
developed contrast nephropathy ranged between 16%
(18/110) and 24.5% (27/110), depending on the defin-
ition of contrast nephropathy (Table 2). There was no
difference between the placebo and the NAC groups, ir-
respective of the definition of contrast nephropathy.
The variations in creatinine and cystatin C concentra-
tions on days 2, 4 and 10 in both groups are reported in
Figure 2. The evolution from baseline to day 10 in cre-
atinine and cystatin C levels concentration was not dif-
ferent between the two groups. At Day 10, both cystatin
C and creatinine were lower than baseline suggesting
that acute renal insufficiency was participating in the
renal impairment observed at day 0 (Table 3).
None of the sensitivity analyses, performed to explore
the impact of loss to follow-up or death, led to a quanti-
tatively different result: all p-value ranged between 0.30
and 0.99. In particular, the composite event of death or
acute kidney injury occurred in 14 (24%) of 58 patients
(after exclusion of the patient lost to follow-up) in the
placebo group, and in 18 (33%) of 54 patients in NAC
group (including the 2 patients who died at day 0).
A correlation coefficient was computed between cre-
atinine levels and cystatin C levels at day 2, 4 and 10.
The correlation was of 0.87 at day 2, 0.83 at day 4 and
0.67 at day 10 demonstrating a good congruence of the
two measures.
No side effects attributed to NAC injection were ob-
served throughout the study.
Discussion
This study demonstrates that ultra-high dose intraven-
ous NAC does not prevent contrast-induced nephropa-
thy in patients with impaired renal function undergoing
emergency contrast CT-Scan, whatever the definition
used for the condition and independently of the use of
creatinine or cystatin C as markers of renal function.
In this work, we used both the classical definition of
contrast nephropathy (25% increase in serum creatinine
or absolute increase of 44 umo/l of creatinine), as well
as cystatin C and AKIN criteria. AKIN critera have been
Table 1 Patients characteristic with regard to the inclusion groups
Characteristics Placebo (n = 59) NAC (n = 55)
Age (years) 78.2 ±11.8 78.1 ± 12.0
Sex (M/F) 29/30 28/27
BMI (kg/m2) 24.4 ± 4.6 25.0 ± 4.8
Diabetes 11 (19%) 15 (27%)
Blood pressure (mmHg)
Diastolic 69.1 ± 11.7 67.0 ± 17.2
Systolic 129.5 ± 20.8 132.9 ± 22.5
Contrast medium (mL) 117.7 ± 3.2 117.4 ± 1.8
Creatinine (μmol/L) 133.5 ± 34.8 132.4 ± 34.8
Cystatin C (mg/L) 1.9 ± 0.5 1.9 ± 0.6
eGFR (MDRD) (ml/min/1.73) 41.7 ± 1.2 42.7 ± 1.2
Antibiotics 16 (27%) 16 (29%)
Angiotensin-converting enzyme inhibitor (ACE-1 inhibitor) 28 (48%) 25 (45%)
Non-steroidal antiinflammatory drugs (NSAIDS) 1 (2%) 5 (9%)
Diuretics 27 (46%) 25 (45%)
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tality contrast nephropathy in ICU patients [7]. The use
of different definition did not modify the fact that iv
NAC did not protect against contrast nephropathy, but
altered the prevalence of events in our population as it
could range from 16 to 24.5% depending on the defin-
ition used. More studies are needed to determine which
definition best predicts mortality in ER patients after
contrast injection.
This study focuses on a poorly studied and fragile
population, namely patients from the ER with elevated
creatinine levels undergoing emergency CT-Scan. This
population is important since it is a large population in
which standard preparation before contrast injection is
impossible due to time constraints. In addition these pa-
tients usually require rapid and often multiple radiologic
examinations. Furthermore, appreciation of the basal
renal function of these patients is difficult given a usually
unique measurement of creatinine level available. In this
study, we observe that approximately one out of fourTable 2 Occurrence of contrast nephropathy (several
definitions) according to the group of inclusion (placebo
or n-acetylcysteine)
Event Placebo NAC P-value
(n = 58) (n = 52)
25% increase of creatinine
or cystatin C
13 (22.4%) 14 (26.9%) 0.66
25% increase creatinine 10 (17.2%) 8 (15.4%) 0.99
25% increase cystatin C 9 (15.5%) 9 (17.3%) 0.99
AKIN stage 1 11 (19.0%) 13 (25.0%) 0.49
AKIN all stages 12 (20.7%) 13 (25.0%) 0.65patients presenting to the ER with an elevated creatinine
undergoing contrast CT-Scan level will develop contrast
nephropathy. This high incidence differs from the inci-
dence described post angiography or post elective CT
[23], demonstrating that emergency CT in a high risk
population is still an important cause of AKI. It is how-
ever probable that a significant percentage of these ob-
served AKI are multifactorial. Indeed, according to the
severity of the medical conditions and the emergency
setting, associated ischemic AKI might contribute to this
high incidence. The study was not designed for this
purpose but each patient was treated according to the
medical illness necessitating the emergency CT SCAN,
which includes treatments to prevent or minimize AKI.
This is illustrated by the decrease in mean creatinine at
Day 10 as compared to baseline creatinine. Nevertheless,
we do not think that it does change the conclusion of
the study regarding the role of NAC in this setting as
our results demonstrate than NAC administration does
not alter this renal evolution. The search for efficient and
rapid means of prevention of contrast nephropathy in pa-
tients with decreased renal function undergoing emer-
gency CT is therefore of paramount importance and
should take into account the risk of multifactorial AKI.
NAC possesses potential anti-oxidant and hemody-
namic properties that have been hypothesized to protect
against contrast nephropathy. Since 2000 and the princeps
study from Tepel [13], it has been used extensively for
renal protection together with hydration before contrast
medium use. However, data in the literature are variable
and even meta-analysis are conflicting due to variation of
protocols used, heterogeneicity of studies and to publi-
cation bias toward positive studies in either oral or
Figure 2 Median and dispersion of the evolution of creatinine
and cystatin C after CT. (a) Median and dispersion of the evolution
of creatinine at day 0, day 2, day 4 and day 10 after CT in the
N-acetylcysteine group (white) and in the control group (grey);
(b) Median and dispersion of the evolution of cystatin C at day 0,
day 2, day 4 and day 10 after CT in the N-acetylcysteine group
(white) and in the control group (grey).
Table 3 Mean increases in creatinine and cystatin C on
days 2, 4 and 10 compared with day 0, in the two groups
Placebo NAC P-value
(n = 58) (n = 52)
Day 2
Creatinine −3.60 ± 35.84 −3.66 ± 38.69 0.96
Cystatin C −0.02 ±0.43 0.06 ± 0.44 0.30
Day 4
Creatinine −8.25 ± 65.62 −8.37 ± 36.52 0.37
Cystatin C −0.04 ± 0.57 −0.04 ± 0.41 0.30
Day 10
Creatinine −14.94 ± 75.53 −16.53 ± 25.23 0.25
Cystatin C −0.12 ± 0.54 −0.07 ± 0.34 0.27
Peak increase
Creatinine 9.38 ± 70.91 4.63 ± 38.14 0.54
Cystatin C 0.06 ± 0.56 0.17 ± 0.43 0.07
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largest trial on oral NAC to date observed no effect of this
drug in preventing contrast nephropathy post angiography
[28]. However Marenzi and collegues describe a dose
dependent protection of NAC, potentially contributing to
the variability of results [17]. High doses (6000 mg over
48 h, the first 1200 mg iv before contrast media, 4800 mgorally after contrast media) seems indeed to give a better
protection than low doses (3000 mg over 48 h). This may
be related to a lower antioxidant effect due to a lower first
pass liver generation than in the oral route. This study is
the first one focusing on ultra high dose intravenous NAC
in the ER population in prevention of contrast nephropa-
thy. Our observation does not substantiate a beneficial
role of even ultra high doses of intravenous NAC, admin-
istrated within 1 hour before CT, for preventing CN as
this treatment was unable to decrease the rate of contrast-
induced nephropathy after emergency CT. Although this
therapy may appear interesting given its low price and few
secondary effects, its administration may result in a false
security for the team in charge. This may also lead to
under consideration of alternative imagery method or
delaying contrast injection in this population. Proper hy-
dration stays the main therapy also in the emergency set-
ting. A 0.9% saline infusion is generally recommended for
the hydration of patients with renal failure prior and after
injection of contrast media [29]. However, in an emer-
gency setting, when large quantity of fluids have to be ad-
ministrated in a short period of time, in patients with
uncertain cardiac function, we consider that the use of a
0.45% solution [30] is more appropriated to avoid acute
pulmonary edema.
A role of NAC on creatinine secretion independently
of kidney filtration has been reported by Hoffman and
collegues [31]. To correct for this, we also measured
cystatin C at all time points of our study. We observed
no effect of NAC on AKI based on creatinine or cystatin
C level. Furthermore, cystatin C and creatinine levels
showed a good correlation at all time points, arguing
against a major role of intravenous NAC on creatinine
secretion.
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tion is relatively small and we cannot exclude a minor
effect of NAC that might have been detectable in a lar-
ger cohort. However, such a small effect would probably
not be relevant in clinical practice. Second our selection
criteria were based on a single creatinine level measure-
ment in the ER. We may therefore have mixed acute and
chronic cases of renal impairment, rendering our popu-
lation less homogenous than in previous studies but
closer to everyday practice in the ER. The high rate of
CN demonstrates that this population was in any cases
vulnerable. Finally, the contrast medium dose used for
CT-Scan is generally lower than for cardiac angiography
which has been the situation mostly studied regarding
NAC effect. Despite these limitations, the follow up of
patients with two renal markers, the very high dose of
NAC and different definitions of AKI used are strong ar-
guments against an effect of IV NAC on AKI prevention
in patients presenting on the ER with a decreased esti-
mated clearance and undergoing contrast CT-Scan.
Conclusions
In summary, contrast-induced nephropathy incidence is
high in patients with a low estimated GFR undergoing an
emergency CT-Scan. Intravenous NAC at high dose is not
more efficient in this population than hydration alone for
prevention of contrast nephropathy and should not be
used in this setting.
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